Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > ViroLogic and ACLARA BioSciences Announce Merger

June 1st, 2004

ViroLogic and ACLARA BioSciences Announce Merger

Abstract:
ViroLogic, Inc. and ACLARA BioSciences, Inc. today announced that they have entered into a definitive merger agreement to create an industry-leading company to develop and commercialize advanced molecular diagnostics for personalized medicine focused on oncology and infectious diseases. The combined company will leverage ViroLogic's commercial laboratory, patient testing and pharmaceutical drug development business, and innovative technology with ACLARA's proprietary molecular assay platform known as the eTag(TM) System.

Source:
ACLARA

Bookmark:

Related News Press

Investments/IPO's/Splits

Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013

Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013

Harris & Harris Group Notes the Sale of a Second D-Wave Quantum Computer May 16th, 2013

Nanometrics Announces Upcoming Investor Events May 14th, 2013

Nanomedicine

Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013

Microneedle-Delivered Nanoparticles Boost Antitumor Vaccines May 20th, 2013

New Nanopore Sensor Simplifies Analysis of Methylated DNA May 20th, 2013

Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013